drugset / Trial / NCT05777031
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
Phase 4
Active not recruiting
12 enrolled
University of Miami
Endo USA Inc., a Keenova Therapeutics Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.
Timeline
- Start
- 2023-10-02
- Primary completion
- 2027-01-15
- Completion
- 2027-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.58 mg | Other |